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ABSTRACT: The recent discovery of the fourth generation
EAI045 allosteric inhibitor, which potently and selectively
inhibits mutant EGFR, represents an important step forward
for the treatment of non-small cell lung cancer. However, the
structural determinants of EAI045 selectivity with respect to
the wild type (wt) protein have not been fully investigated. To
this aim, we performed a comparative analysis of long-scale
molecular dynamics simulations and binding free energy
calculations on wt and T790M EGFR in complexes with the
EAI001 and EAI045 allosteric ligands. Unexpectedly, we
found that the observed selectivity for T790M EGFR over wt
is not due to more favorable interactions of the two ligands
with the mutated gatekeeper residue, as previously suggested.
Rather, the allosteric ligands were engaged in a direct hydrogen bond with the Asp855 residue of the DFG motif in mutant
T790M but not in wt, in which the hydrogen bond was found to be water-mediated. Per-residue decomposition of binding free
energies suggests that the loss of a direct interaction with Asp855 is the main cause of inhibitor selectivity. Moreover, the
possibility that the allosteric ligands and adenosine triphosphate may have synergistic binding effects, as previously observed in
MEK allosteric inhibitors, was investigated. Altogether, the results suggest that ligand selectivity arises from direct hydrogen
bonds with the Asp855 side chain, and that the design of mutant-selective inhibitors should be focused on ligands that form
direct hydrogen bonds with Asp855 in T790M EGFR but not in wt EGFR. These results may provide useful hints for future
structural design of mutant-selective allosteric inhibitors that spare wt EGFR, which is a highly desirable goal.
■ INTRODUCTION
Developing mutant-selective inhibitors of the tyrosine kinase
epidermal growth factor receptor (EGFR) is of utmost
importance. To date, six FDA-approved EGFR inhibitors are
used in the clinic to treat non-small cell lung cancer (www.
brimr.org/PKI/PKIs.htm; accessed on Nov 19, 2018).
Unfortunately, the T790M secondary mutation of the
gatekeeper residue is one of the main causes of drug resistance
to first (e.g. gefitinib and erlotinib) and second generation (e.g.
afatinib and dacomitinib) adenosine triphosphate (ATP)-
competitive EGFR inhibitors.1,2 Indeed, the gatekeeper
mutation is able to enhance the affinity for the ATP substrate.3
Recently, the efforts potentially able to circumvent this
problem were directed toward the identification of allosteric
ligands, which bind to less conserved binding pockets and
stabilize the inactive conformation of the receptor, whose
dimerization is hampered by displacement of the regulatory
αC-helix.4 Structure-based design of allosteric inhibitors is a
challenging task because of the scarcity of structural
information.5 In fact, the first crystal structure of an allosteric
inhibitor in the complex with mutant EGFR was reported only
in 2016 (PDB code: 5D41).6 The mutant-selective inhibitor
EAI001 binds to an inactive conformation of T790M EGFR
and is located in the allosteric pocket created by an outward
shift of the αC helix (see Figure S1). The crystallographic
structure of the complex with the optimized derivative EAI045
was obtained in late 2018, and presents an additional mutation
known to confer resistance to ATP-competitive irreversible
inhibitors (C797S).7 Very recently, Kannan et al. reported a
molecular dynamics investigation of EAI045 complexes with
various mutant EGFRs, but the reasons for the observed
selectivity with respect to the wild type (wt) EGFR protein
were not the matter of investigation.8 Indeed, to date, crystal
structures or computational models of the allosteric EAI
compounds in the complex with wt EGFR have not been
reported. EAI001 and its optimized derivative EAI045 proved
to be selective inhibitors of mutant EGFR,6 but the selectivity
determinants that discriminate against wt have not been
specifically addressed.
In this study, we report the results of a comparative long-
scale (2 μs) molecular dynamics and binding free energy
prediction analysis performed on wt and T790M EGFR
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complexes with the two allosteric ligands EAI001 and EAI045.
Specifically, we propose and validate a binding mode of the
EAI compounds on wt EGFR, then we compare it with the
binding mode observed in the respective T790M EGFR
mutant complexes. The results shed light on an interesting and
far from obvious explanation to the observed selectivity, which
points the attention to a water molecule that bridges the
allosteric ligand to the DFG motif in wt, but not in T790M
EGFR. Moreover, we addressed the questions as to why
EAI045 is more potent than EAI001 and the possibility that
the allosteric ligands and ATP may have synergistic binding
effects, as previously observed in MEK allosteric inhibitors.9,10
■ RESULTS AND DISCUSSION
Generation of EGFR/EAI Complexes. The crystal
structure of EAI001 in the complex with T790M EGFR
(PDB code: 5D41, chain A)6 was used to perform molecular
dynamics simulations of the T790M EGFR/EAI001/ATP
complex (Figure S1). As for the complex with the optimized
inhibitor EAI045, the starting complex was generated by
docking EAI045 to the 5D41 structure (see Methods), so that
all further analyses could be performed on the same protein
structure. Remarkably, the superimposed docked pose resulted
quite similar to the crystallographic pose of EAI045 in the
complex with C797S/T790M EGFR reported later (PDB code
5ZWJ),7 with a root mean square deviation (RMSD) of only
0.81 Å, despite the absence of Mg-ATP and the presence of an
additional mutation (C797S) in this crystal structure. To be
consistent with the 5D41 structure, we generated a ternary
T790M EGFR/EAI045/ATP complex, whereas the recently
released structure was crystallized without ATP. Regarding the
generation of wt-EGFR/EAI complexes, we were faced with
the notion, as reported in the article by Jia et al., that the
binding mode of EAI001 seems to be incompatible with the
structure of wt EGFR.6 In fact, in the structure analyzed by the
authors (PDB code: 2GS7), and lately also by Kannan and co-
workers,8 the allosteric pocket is partially occluded by a short
helix at the beginning of the activation loop, which is typical of
kinases in the inactive conformation. We recently reported a
comprehensive analysis and comparison of the structural
kinome, which explored the different geometrical and physico-
chemical properties of the allosteric pocket by taking the
T790M EGFR crystal structure of 5D41 as a reference.11 Based
on this analysis, the PDB structure of wt EGFR in the complex
with a 4-amino-6-arylamino-pyrimidine-5-carbaldehyde hydra-
zine derivative (PDB code 2RGP) had an allosteric pocket
geometrically similar to that of 5D41. Interestingly, this
structure was crystallized with an ATP-competitive ligand
possessing a chemical moiety that extended into the allosteric
pocket, thus resulting in a more open allosteric pocket.12 With
respect to 2GS7, residues Leu858 and Leu861 of this structure
are slightly shifted, thus allowing the EAI inhibitors to dock in
the allosteric pocket with minor adjustment of nearby residue
side chains. In fact, by means of induced fit docking, we were
able to obtain wt EGFR/EAI complexes that closely matched
the crystallographic poses observed in mutant EGFR.
Molecular Dynamics of EAI001 and EAI045 Com-
plexes with wt and T790M EGFR. Each ternary EGFR/
EAI/ATP complex was simulated for over 0.5 μs in water
(periodic boundary conditions), resulting in a total of 2 μs
simulation time. The binding modes of the allosteric inhibitors
and ATP were conserved throughout the entire MD simulation
of all four complexes, as evidenced by the small RMSD’s of
ligand positions reported in Table 1. Likewise, an inspection of
the Cα carbon deviations of the residues composing the
allosteric pocket showed no considerable deviations from the
original position.
The generated MD trajectories were then used to carry out
an analysis of the protein−ligand hydrogen bond networks,
including water-mediated bridge interactions (Table 2). The
analysis of the T790M EGFR/EAI001 MD trajectory
confirmed that the interactions observed in the 5D41 crystal
structure are indeed conserved throughout the MD simulation,
for example the hydrogen bond between the amide nitrogen
N12 and the side chain of Asp855 (Table 2). The hydrogen
bond between Lys745 and the O8 carbonyl of the
isoindolinone ring was not present in the MD simulation,
this residue being preferably engaged in electrostatic
interactions with one of the phosphate oxygens of ATP. The
binding mode of EAI045 closely overlapped that of EAI001,
the additional hydroxyl group forming a hydrogen bond with
the backbone carbonyl of the Phe856 residue of the DFG motif
(Table 2 and Figure 1A). This hydrogen bond is maintained
throughout the entire simulation. Apart from this additional
hydrogen bond and the presence of the fluorine, our
simulations did not point out additional interactions that
may explain the higher inhibitory activity of EAI045 with
respect to EAI001.6
The MD simulations of the two wt EGFR/EAI/ATP
complexes were run using the same protocol described for
mutant EGFR complexes. Again, the average RMSD for ligand
position and protein Cα carbons was relatively small (Table 1).
However, a closer inspection of the hydrogen bond network
resulting from these MD simulations revealed that the
hydrogen bond between the amide nitrogen (N12) and the
Asp855 side chain was not present in the wt simulations
(Table 2). This behavior was observed for both EAI001 and
EAI045. Unexpectedly, the amide nitrogen and the Asp855
side chain were bridged by one water molecule, instead of a
direct hydrogen bond. Moreover, the salt bridge between
Lys745 and Asp855 was lost and never recovered, the Lys745
residue interacting with the O8 carbonyl of the ligand, and the
Asp855 side chain interacting with the Thr854 residue ahead
of the DFG (Figure 1B). Remarkably, this interaction pattern
resulting from MD was not present neither in the mutant
EGFR crystal structures nor in the initial docked complexes.
Therefore, the results obtained in wt EGFR point the attention
Table 1. RMSD (Å) of Protein Cα Carbons and of the
Ligand and ATP Heavy Atoms for Each EGFR/EAI/ATP
Molecular Dynamics Simulation
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to the absence of a direct interaction between the ligand and
the Asp855 side chain, which clearly distinguishes these
complexes from those obtained in mutant EGFR (Table 2).
The ligands are still held in place by the additional interaction
between the carbonyl oxygen O8 and the Lys745, but the
direct interaction with Asp855 is lost. The additional hydroxyl
Table 2. Percentage of the Occurrence of Ligand−EGFR Hydrogen Bonds Sampled by MDsa
aA “/” indicates that the protein does not possess the required group to form the interaction.
Figure 1. (A) Representative structure of the T790M EGFR/EAI045/ATP complex obtained by MD. (B) Representative structure of the wt
EGFR/EAI045/ATP complex obtained by MD. Water molecules are shown as red dots. Hydrogen bonds are highlighted with black dotted lines.
The ATP molecule was omitted for clarity.
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group of EAI045 hydrogen bonded with the backbone
carbonyl of Phe856 for the whole duration of the MD
simulation, as already observed in the MD simulations of
mutant EGFR complexes.
To conclude, the MD simulations suggest that the allosteric
ligands EAI001 and EAI045 form direct hydrogen bonds with
the Asp855 side chain in mutant EGFR, but not in the wt
protein.
Selectivity Determinants from Binding Free Energy
Calculations and Per-Residue Free Energy Decomposi-
tion. To further investigate the origin of the selectivity of EAI
ligands for T790M EGFR, we also calculated the binding free
energies of the two compounds to the respective wt and
mutant proteins. Remarkably, we found that the free energies
of binding of EAI001 and EAI045 to T790M EGFR are around
7 kcal/mol more favorable with respect to those for wt EGFR
(Table 3). This result is in agreement with the experimentally
observed selectivity of EAI compounds for mutant EGFR
(EAI045’s inhibitory activity being 32-fold better for T790M
EGFR over the wt).6 Although absolute free energies
calculated with MM-PBSA are known not to be quantitatively
comparable with experimental binding free energies calculated
from Ki or IC50 values, their relative variations are indeed
relevant and may be qualitatively used for comparative
purposes.13,14 Free energy predictions also suggest that the
binding free energy of EAI045 is around 2 kcal/mol more
favorable than that of EAI001 in both the wt and T790M
EGFR simulations (Table 3), again in agreement with
experimental data.
Finally, to evaluate which amino acid residues contributed
the most to the variations of total binding free energies
reported in Table 3, the calculated total free energies were
decomposed into their per-residue contributions (see
Methods). Figure 2 shows the average contribution of residues
with 0.2 < ΔGMM‑PBSA < −0.2 kcal/mol values. Interestingly,
although Jia et al. proposed that EAI selectivity for mutant
EGFR may be because of favorable interactions of the sulfur of
the thiazole ring with the mutated Met790 side chain, we
found that the relative contribution of the methionine to the
binding free energy was only 0.5 kcal/mol more favorable with
respect to the contribution of the threonine residue of the wt
(Figure 2A). On the contrary, the Asp855 residue contributed
with a much more significant (3.5 kcal/mol) stabilization to
the binding free energy of T790M complexes as opposed to wt
(Figure 2A). This finding is in agreement with our observation
that EAI compounds do not form a direct hydrogen bond with
Asp855 in wt EGFR. Therefore, structures and free energies
agree in saying that most of the selectivity comes from the lack
of a direct hydrogen bond with Asp855 in wt EGFR. Indeed,
while Asp855 has a positive (i.e. unfavorable) ΔGMM‑PBSA
contribution in wt (Figure 2A), the contribution becomes
significantly negative (i.e. favorable) in mutant EGFR. Figure
2A also shows that Lys745 has a slightly more favorable
contribution in the wt-EGFR/EAI045 complex. This is in
agreement with the detected hydrogen bond between the
carbonyl oxygen O8 and the residue side chain. Interestingly,
this additional interaction could not compensate for the loss of
the EAI045-Asp855 hydrogen bond. Finally, Figure 2B
compares the residue contributions to the binding free energy
of EAI001 and EAI045 to T790M EGFR.
As expected, most of the additional stabilization observed for
EAI045 complexes comes from the DFG motif, and in
particular from the Phe856 residue that provides additional 3
kcal/mol stabilization to the overall binding free energy with
respect to EAI001 (Figure 2B). This finding nicely correlates
with the establishment of an additional hydrogen bond via the
hydroxyl group. Asp855, Gly857, and Leu858 also showed
more negative (i.e. favorable) contributions of around 1 kcal/
mol each. It is likely that the additional hydrogen bond with
the Phe856 carbonyl anchors the molecule more tightly to the
DFG motif, resulting in globally stronger interactions. Indeed,
Figure 2C, which compares the residue contributions of
EAI001 and EAI045 complexes with wt EGFR, shows that the
only difference comes from Phe856. Asp855, Gly857 and
Table 3. MM-PBSA Binding Energies (kcal/mol) of EAI001 and EAI045 to wt and T790M EGFRa
EAI001 EAI045
(kcal/mol) wt T790M wt T790M
ternary complex (EGFR/ligand/ATP) including ATP contribution −29.0 ± 3.9 −36.0 ± 3.5 −30.9 ± 4.3 −37.7 ± 3.8
ternary complex (EGFR/ligand/ATP) excluding ATP contribution −32.1 ± 3.9 −37.6 ± 3.4
binary complex (EGFR/ligand) −39.3 ± 4.6 −41.1 ± 4.3
aEnergies were calculated for the ternary complexes (EGFR/ligand/ATP), EGFR/ligand/ATP ternary complexes by excluding the ATP
contribution, and binary complexes obtained by MD simulations of EGFR/ligand complexes (i.e. no ATP in the trajectory).
Figure 2. Binding free energy decomposition profiles (MM-PBSA) of
(A) wt vs T790M EGFR/EAI045/ATP MD simulations; (B) T790M
EGFR/EAI001 vs EAI045/ATP MD simulations; (C) wt EGFR/
EAI001 vs EAI045/ATP MD simulations. Only residues with 0.2 <
ΔGMM‑PBSA < −0.2 kcal/mol values are shown.
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Leu858 do not appear to be affected by the additional
hydrogen bond with the hydroxyl group, in agreement with the
fact that none of them forms a direct hydrogen bond with the
ligand.
Testing a Possible Synergistic Effect of ATP on the
Binding of EAI045. Finally, we investigated whether ATP
could provide synergistic binding effects with the EAI
compounds, as already observed for other type III allosteric
ligands of MEKs.9,10 Although the 5D41 PDB structure was
crystallized with both EAI001 and the ATP derivative AMP-
PNP (phosphoaminophosphonic acid-adenylate ester),6 the
more recent crystal structure of T790M/C797S EGFR in the
complex with EAI045 was obtained without ATP (5ZWJ).
Moreover, our T790M EGFR MD simulations identified direct
interactions between residue Lys745 and ATP, as well as
water-mediated interactions between Thr854, Asp855, and
ATP in wt EGFR MD simulations.
Therefore, we repeated the binding free energy calculations
on the ternary EGFR/EAI045/ATP MD complexes by
excluding ATP from the list of residues contributing to the
overall binding free energy. By excluding the contribution of
ATP, binding free energies were only 1 kcal/mol more
negative in wt EGFR and almost identical in T790M EGFR
(Table 3). Therefore, our results suggest that ATP does not
provide synergistic effects with EAI compounds. Binding free
energies were also calculated by performing additional MD
simulations on the binary EGFR/EAI045 complexes, that is, by
generating new 0.25 μs MD trajectories without bound ATP
(see Methods). In the binary complexes, binding free energies
of EAI045 were around 8 and 3 kcal/mol more favorable than
those calculated in the ternary complexes (Table 3), providing
further evidence of a lack of synergistic effects. This difference
is mainly due to the establishment of a hydrogen bond
between the O8 carbonyl of EAI045 and the Lys745 side chain
(see Supporting Information), which does not have to compete
with the Lys745/ATP ionic interaction observed in the ternary
complexes. This is in agreement with what is proposed by
Zhao et al., who suggested that without the ATP molecule
Lys745 shifts toward the carbonyl O8 of the EAI045
compound.
■ CONCLUSIONS
Mutant-selective inhibitors binding to EGFR with an allosteric
mechanism have been recently described. Despite being
selective for mutant T790M EGFR, a structural explanation
of such biological behavior is still missing.
In an effort to identify structural motifs explaining the
different affinity of EAI001 and EAI045 allosteric inhibitors for
the wt and mutant EGFR proteins, molecular dynamics and
binding free energy calculations were performed. To this aim,
0.5 μs MD simulations of the two EAI compounds in complex
with wt and T790M EGFR proteins were performed. Then, the
obtained trajectories were analyzed in order to investigate and
compare the resulting hydrogen bond networks. Results from
these analyses showed that the Asp855 residue plays a key role
in ligand selectivity. In fact, while this residue establishes direct
hydrogen bonds with the EAI compounds in both the X-ray
and MD-generated T790M-EGFR structures, this interaction
becomes water-mediated in wt EGFR, a water molecule
bridging the amino group of the EAI ligands to the Asp855
side chain. The different hydrogen bonding patterns are
graphically illustrated in Figure 3 panel A (T790M) and panel
B (wt). Binding free energy calculations with the MM-PBSA
methods clearly indicated that the compounds bind preferen-
tially to T790M EGFR and that EAI045 binds more tightly
than EAI001, in agreement with the experiment. Per-residue
decomposition of binding free energies clearly pointed to the
discriminating role of Asp855, in agreement with the observed
structural differences arising from the MD simulations.
In conclusion, we propose that ligand selectivity arises from
direct hydrogen bonding of the ligand with the Asp855 side
chain in mutant EGFR but not in wt, in which the interaction
is water-mediated and much weaker. Therefore, the design of
mutant-selective inhibitors should be focused on ligands that
form direct hydrogen bonds with Asp855 in T790M EGFR but
not in wt EGFR structures, as exemplified in Figure 3 panel A
(T790M) and panel B (wt). The different hydrogen bonding
patterns depicted in the two panels may help to devise ad hoc
structure-based pharmacophores or docking screening experi-
ments to assist the design of mutant-selective ligands. It will be
interesting to see if future experiments will confirm our
Figure 3. 2D representation of the binding mode of EAI045 to T790M EGFR (panel A) and wt EGFR (panel B), according to MD simulations.
Relevant explicit waters and hydrogen bonds are showed. The ATP molecule was omitted for clarity.
ACS Omega Article
DOI: 10.1021/acsomega.8b03256
ACS Omega 2018, 3, 16556−16562
16560
predictions. Meanwhile, our results may provide useful hints
for the discovery of mutant-selective allosteric ligands of
EGFR, which is a highly desirable goal.
■ MATERIALS AND METHODS
Structure Preparation. Crystal structures were down-
loaded from the Protein Data Bank and processed with the
Schrödinger Suite 2014-3 Protein Preparation Wizard (PPW)
tool. PPW automatically adjusted the ionization and
tautomerization state of the protein at a neutral pH (PROPKA
was used to predict the pKa of residues at pH = 7), set the
orientation of any misoriented groups (Asn, Gln, and His
residues), and optimized the hydrogen bond network. All
residues were found to be in standard ionization states. Chain
B of the PDB structure 5D41 was deleted, as it is not bound to
the EAI ligand. Uncapped amino acidic N and C terminals
were treated with the “cap termini” option. The choice of the
crystal structures of wt EGFR to be used for docking was based
on our recent work that compared the geometrical and
physico-chemical features of the allosteric pocket in the
structural kinome.11 This identified 2RGP as a high-resolution
crystal structure of wt EGFR, having a close match of the
allosteric pocket with that of 5D41. The PDB structure of wt
2RGP was superimposed to that of 5D41, and the EAI001
ligand was added to the allosteric pocket. In a final step, the
ligand−protein complexes were refined to relieve steric clashes
performing a restrained minimization on the proteins’ atoms.
The OPLS 2005 force field was used, and the minimization
was terminated when a final RMSD of 0.30 Å with respect to
the input protein coordinates was reached. The 3D structures
of ligands EAI001 and EAI045 were drawn with Maestro, and
prepared with the LigPrep module. Induced Fit Docking (IFD)
was used to simulate the binding modes of the EAI compounds
in the wt and T790M mutant proteins.15 IFD was performed
with standard settings except for an additional trimming of the
Leu858 and Met766 side chains. A maximum number of 20
poses was saved for each ligand and submitted to the ensuing
prediction of side-chain orientation of residues within 5 Å
around the ligand, as calculated by Prime. After the Prime
minimization, a Glide SP redocking of each protein−ligand
complex structure was performed. Finally, the binding energy
(IFDScore) for each output pose was calculated to score the
resulting complexes. Resulting poses were visually analyzed
and compared with the corresponding initial crystal structures.
Molecular Dynamics Protocol. The T790M EGFR/
EAI001/ATP MD simulation was performed starting from the
crystal structure of 5D41, whereas the starting point for the
other simulations were the top-scoring complexes obtained by
IFD, as described above. Atomic charges of the ligand were
computed with antechamber (BCC charge method). The
corresponding protein was saved in the PDB format, deleting
all hydrogen atoms. The topologies were created with the
program tleap of the Amber14 suite. Parameters from the
Manchester University AMBER parameter database (http://
research.bmh.manchester.ac.uk/bryce/amber/) were used for
ATP16 and Mg ion.17 The protein−ligand complex was
enclosed in a truncated octahedral TIP3P water box with a
radius of 10 Å. Counter ions were added to neutralize the
complexes; 5 Na+ ions were required to neutralize T790M
EGFR (5D41) whereas 3 Cl− ions were added to neutralize the
wt EGFR (2RGP) complexes. For all the simulations, the
coordinates of the phosphoaminophosphonic acid-adenylate
ester (AMP-PNP, PDB ID: ANP) and Mg ion were obtained
from the 5D41 PDB structure (chain A). The nitrogen atom of
AMP-MNP was edited to an atom of oxygen to obtain the
ATP structure. All molecular dynamics runs were performed
using Amber14.18 An initial minimization of the solvated
complexes was carried out on the whole system. The
minimization consisted of 1000 steps of steepest descent
minimization followed by 1000 steps of the conjugate gradient
minimization. The minimized system was heated to 300 K with
a constant volume 0.5 ns simulation, whereas the protein Cα
carbons were held fixed with a 10 kcal/mol constraint.
Subsequently, the system was re-equilibrated with a 3 ns
constant pressure MD to allow adjustment of the density of the
system. The pressure was set to 1 atm with isotropic position
scaling (ntp = 1). Finally, the constraints on the Cα carbons
were released, and a MD production run without constraints at
1 atm constant pressure was calculated. The total simulation
time for each complex was set to 0.5 μs. A time step of 2 fs was
set, and the SHAKE algorithm was used to constrain bonds
involving hydrogen atoms. Analysis of the resulting trajectories
was carried out by means of calculation of rmsd, hydrogen
bond network, and water occupancy using the program cpptraj
of the Amber14 suite (using the rms, hbond and watershell
commands, respectively).
MM-PBSA Calculations. Binding free energy calculations
were performed by means of the MMPBSA.py module of the
Amber14 suite. Prior to the calculations, counter ions were
removed from the MD trajectory coordinate file. New prmtop
files were calculated using cpptraj for the solvated and
unsolvated complexes and for the isolated receptor and ligand
structures. MM-PBSA parameters were set as in previous
investigations.13 A total of three free energy calculations were
performed: (i) on the ternary EGFR/EAI045/ATP complexes;
(ii) an additional calculation on the same trajectory, but
excluding the ATP contribution by extracting the ATP
molecule from the trajectory; (iii) on the binary EGFR/
EAI045 complexes MD. Moreover, binding free energies were
decomposed based on their per-residue contributions using the
MMPBSA.py module (idecomp = 1).
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